Amphastar (AMPH) - Sell a Bull Put Spread to Collect Elevated Premiums After a Steep Pullback

Hook & thesis

Amphastar Pharmaceuticals (AMPH) has retraced hard from last year's highs and is now trading around $18.18. For traders comfortable with defined-risk option selling, I prefer a mid-term bull put spread: it lets you collect elevated premium while owning asymmetric upside if the stock mean-reverts toward prior support levels. The company carries tangible fundamentals - $824M market cap, positive free cash flow of $121.2M and a P/E in the single digits - that make a disciplined put-sell reasonable at these levels.

In short: sell a short-dated, defined-risk put spread to collect credit while the market digests near-term weakness. The trade benefits from depressed RSI (21.6), lower absolute price proximity to the 52-week low ($17.03) and elevated option premiums that improve expected return for sellers.

Why the market should care - the business in two paragraphs

Amphastar develops, manufactures and sells technically challenging generic and proprietary injectables, inhalation and intranasal products, and insulin API. Its Finished Pharmaceutical Products include items such as Primatene Mist, enoxaparin and naloxone, while the API segment supplies insulin intermediates externally and for internal development. That mix gives Amphastar exposure to both steady generics/critical care demand and higher-margin API sales.

From a shareholder perspective the balance sheet and cash generation underpin the bull-put approach. Market cap is roughly $824M, enterprise value about $1.265B and free cash flow sits at $121.2M. At a trailing P/E ~8.4 and EV/EBITDA around 6.4, the stock is not priced for perfection. If the company avoids a material near-term negative re-rating, time decay and any mean-reversion in price create a favorable backdrop for selling puts with limited downside.

Key fundamental and technical data points

• Current price: $18.18.
• Market cap: $824M; enterprise value: $1.265B.
• Earnings per share: $2.16; price-to-earnings: ~8.4.
• Free cash flow: $121.2M; price-to-free-cash-flow: ~6.8.
• 52-week range: $17.03 - $31.26. Current price sits close to the 52-week low.
• Technicals: RSI 21.6 (oversold); SMA/EMA stack well above current price, suggesting mean-reversion potential.
• Short interest: roughly 3.65M shares with days-to-cover recently near 6.1, which is not an outsized short base but worth noting for intraday squeezes.
• Volume: recent day traded volume ~603k vs two-week avg ~735k.

Why a bull put spread now?

There are three reasons I prefer a defined-risk put sell (bull put spread) over buying calls or naked short puts here:

• Premiums are rich enough to make credit attractive. Recent commentary flagged rising implied volatility in Amphastar options, increasing the credit received for selling puts and improving the expected risk/reward on a spread.
• The fundamentals provide a margin of safety. Amphastar generates meaningful free cash flow ($121.2M) and trades at a modest EV/EBITDA (~6.4). At current prices the valuation looks reasonable if results are stable.
• Technically the name is oversold (RSI 21.6) and close to the 52-week low ($17.03). A mean-reversion bounce, even to the low-$20s, would render the sold put harmless and allow the seller to keep most or all of the credit.

Concrete trade - the setup

Below is a concrete, actionable bull put spread designed for a mid-term timeframe. Expiration and strikes are examples that balance premium collected with defined downside protection. Adjust size to risk tolerance.

Position sizing note: with max risk ~$190 per contract, scale contracts to limit portfolio exposure. For example, risking $1,900 total equals 10 contracts assuming the $190 max loss.

Why these strikes?

The 17.50 short put sits slightly below the current market price and above the 52-week low, offering a conservative buffer. The 15.00 long put caps downside, converting the position into a defined-risk trade. With implied volatility elevated, that $2.50 width can be purchased relatively cheaply while collecting meaningful credit.

Catalysts that could help the trade

• Sector and policy tailwinds - the broader generic/specialty pharma sector has shown pockets of stability and regulatory clarity; past policy moves that excluded generic drugs from tariffs helped sentiment.
• Operational stability - continued positive cash generation and steady API and finished product demand will limit downside risk and support valuation.
• Technical mean-reversion - an oversold bounce (RSI 21.6) could lift the shares back toward the mid-$20s, allowing premium capture with low realized risk.
• Volatility contraction - if implied volatility retraces, the sold put depreciates in value and you can buy to close at a profit even without a large bullish move.

Risks and counterarguments

• Downside event risk - a negative earnings surprise, product recall or regulatory setback could push shares below the short strike and inflict the maximum loss. That is the primary risk for any put-selling strategy.
• Competitive pricing pressure - aggressive generic pricing or new entrants for key products could reduce revenue and margins, undermining the valuation cushion.
• Liquidity & execution risk - option credit assumptions are illustrative; actual premiums fluctuate intraday. Wide bid-ask spreads could make entry or exit more expensive than planned.
• Noisy sector moves - sector rotation or macro shocks can push stocks sharply lower irrespective of company fundamentals; a defensive stop is vital.
• Counterargument: you could argue the market is signaling real structural deterioration - the stock is near the 52-week low for a reason and short-term oversold readings can become deeper traps. If Amphastar's top-line or margins flash worse-than-expected, selling puts is a losing posture. That is why I keep the width limited and use the 52-week low as an explicit stop level.

What would change my view

I will reconsider this bull-put stance if any of the following occur: a material downgrade to growth or margin guidance, visibility of persistent pricing pressure across core generics, or a sustained rise in short interest combined with deteriorating liquidity that indicates structural weakness rather than a cyclical pullback. Conversely, a clearer operational catalyst - a beat and raise quarter or a sign of improving API demand - would make me consider more aggressive spread structures or directional long exposure.

Conclusion and final checklist

Amphastar's current price near $18.18, single-digit P/E and strong free cash flow argue the downside is at least bounded for patient traders. Elevated option premiums and an oversold technical backdrop create an attractive environment for a defined-risk put-sell. The recommended trade is a mid-term bull put spread (Apr 30, 2026 17.50/15.00) entered for a target credit near $0.60, with a stop at $17.03 and a profit-taking plan at 50-80% of max gain.

If you use this idea, size the position to where a worst-case loss is tolerable, confirm live option pricing meets the targeted credit, and keep the spread small if you are early in your screening. This is a pragmatic, income-oriented trade that profits from time decay and modest mean reversion, not from a big binary event.

Trade summary (quick checklist)

• Entry: AMPH $18.18; sell Apr 30, 2026 17.50 put / buy Apr 30, 2026 15.00 put.
• Target credit: ~ $0.60 (example) - confirm live price before entry.
• Max loss: $1.90 per share / $190 per contract.
• Stop: close if AMPH <= $17.03 or if spread value exceeds 50% of max loss.
• Horizon: mid term (45 trading days) - target expiration 04/30/2026.

If the facts change materially - weaker cash flow, adverse regulatory news, or a failing of core products - I'll shift to neutral or defensive option structures. For now, a measured, defined-risk bull put spread is my favored way to express a constructive, income-biased view on AMPH.